EasySep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Kit II

Immunomagnetic positive selection of human CD138+ cells from whole blood and bone marrow

New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

EasySep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Kit II

Immunomagnetic positive selection of human CD138+ cells from whole blood and bone marrow

From: 825 USD
Catalog #
(Select a product)
Immunomagnetic positive selection of human CD138+ cells from whole blood and bone marrow
Add to Wish List

Product Advantages


  • Fast and easy-to-use

  • No columns required

What's Included

  • EasySep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Kit II (Catalog #17887)
    • EasySep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Cocktail, 3 x 1 mL
    • EasySep™ Dextran RapidSpheres™ 50100, 3 x 1 mL
    • EasySep™ RBC Lysis Buffer 10X Concentrate, 10 mL (Catalog #20110)
  • RoboSep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Kit II (Catalog #17887RF)
    • EasySep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Cocktail, 3 x 1 mL
    • EasySep™ Dextran RapidSpheres™ 50100, 3 x 1 mL
    • EasySep™ RBC Lysis Buffer 10X Concentrate, 10 mL (Catalog #20110)
    • RoboSep™ Buffer (Catalog #20104) x 2
    • RoboSep™ Filter Tips (Catalog #20125) x 2
Products for Your Protocol

Overview

Isolate highly purified human CD138+ (syndecan-1) cells from fresh bone marrow or whole blood samples by immunomagnetic positive selection, with the EasySep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Kit II. Widely used in published research for more than 20 years, EasySep™ combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep™ positive selection procedure, desired cells are labeled with antibody complexes recognizing CD138+ (syndecan-1) and dextran-coated magnetic particles. The cocktail in this kit also contains an antibody to human Fc receptor to prevent non-specific binding. Labeled cells are separated using an EasySep™ magnet and by simply pouring or pipetting off the unwanted cells. The cells of interest remain in the tube. Following magnetic cell isolation, the desired CD138+ cells are ready for downstream applications such as fluorescence in situ hybridization (FISH), flow cytometry, culture, or DNA/RNA extraction. The CD138 antigen is expressed on normal and malignant plasma cells (but not mature B cells).

This product replaces the EasySep™ Human Whole Blood and Bone Marrow CD138 Positive Selection Kit (Catalog #18387) for even faster cell isolations.

Take our free On-Demand CD138+ Cell Isolation Course to learn how to process bone marrow samples and isolate CD138+ plasma cells to increase sensitivity in FISH testing for multiple myeloma. You can also browse our Frequently Asked Questions (FAQs) about isolating CD138+ plasma cells to improve FISH sensitivity.

Learn more about how immunomagnetic EasySep™ technology works or how to fully automate immunomagnetic cell isolation with RoboSep™. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.

Magnet Compatibility
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• RoboSep™-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
Myeloma, Plasma
Species
Human
Sample Source
Bone Marrow, Whole Blood
Selection Method
Positive
Application
ELISA
Brand
EasySep, RoboSep
Area of Interest
Immunology

Data Figures

Starting with fresh whole blood spiked with a multiple myeloma cell line, U266, the CD138+ cell content of the selected fraction typically ranges from 83.7 - 98.3%. In the above example, the purities of the start and final isolated fractions are 9.1% and 90.4%, respectively. NOTE: For samples with CD138+ starting frequency < 10 - 15%, the CD138+ purity of the isolated fraction may be variable. NOTE: Red blood cells were removed from the start sample by lysis prior to flow cytometry.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Safety Data Sheet 1
Catalog #
17887
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17887
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17887
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17887RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17887RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17887RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
17887RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (1)

Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. R. Sakemura et al. Blood 2022 jun

Abstract

Pivotal clinical trials of B-cell maturation antigen-targeted chimeric antigen receptor T (CART)-cell therapy in patients with relapsed/refractory multiple myeloma (MM) resulted in remarkable initial responses, which led to a recent US Food and Drug Administration approval. Despite the success of this therapy, durable remissions continue to be low, and the predominant mechanism of resistance is loss of CART cells and inhibition by the tumor microenvironment (TME). MM is characterized by an immunosuppressive TME with an abundance of cancer-associated fibroblasts (CAFs). Using MM models, we studied the impact of CAFs on CART-cell efficacy and developed strategies to overcome CART-cell inhibition. We showed that CAFs inhibit CART-cell antitumor activity and promote MM progression. CAFs express molecules such as fibroblast activation protein and signaling lymphocyte activation molecule family-7, which are attractive immunotherapy targets. To overcome CAF-induced CART-cell inhibition, CART cells were generated targeting both MM cells and CAFs. This dual-targeting CART-cell strategy significantly improved the effector functions of CART cells. We show for the first time that dual targeting of both malignant plasma cells and the CAFs within the TME is a novel strategy to overcome resistance to CART-cell therapy in MM.
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more